ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Tyra Biosciences launches with $50 million for small-molecule drugs for cancer

by Ryan Cross
January 24, 2020 | APPEARED IN VOLUME 98, ISSUE 4

 

Tyra Biosciences has raised $50 million in series A financing to develop small-molecule drugs for treatment-resistant cancers. The Carlsbad, California–based start-up is focused on cancers that have acquired resistance to tyrosine kinase inhibitors, a class of more than 40 approved drugs. Tyra was founded in 2018 by Daniel Bensen, former head of immunology and protein chemistry at Cidara Therapeutics, and Todd Harris, founder and former CEO of Sienna Labs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment